Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed vs Docetaxel in Advanced NSCLC
NCT00391274Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival at 30 months. Started Oct 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00391274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391274.